Literature DB >> 2503515

Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin.

C B Siegall1, V K Chaudhary, D J FitzGerald, I Pastan.   

Abstract

Pseudomonas exotoxin is composed of three structural domains that are responsible for cell recognition, membrane translocation, and ADP-ribosylation. The substitution of the cell recognition domain (domain Ia) with a growth factor such as transforming growth factor alpha (TGF alpha), creates a cell-specific cytotoxic agent, TGF alpha-PE40, which kills cells bearing epidermal growth factor (EGF) receptors. We have used TGF alpha-PE40 to define the role of sequences in domains II, Ib, and III. Various mutations were made in these domains and mutant forms of TGF alpha-PE40 expressed in Escherichia coli. Mutant proteins were then tested for their ADP-ribosylation, EGF receptor-binding, and cell-killing activities. Additionally, the amino boundary of domain III, which contains the ADP-ribosylation activity, was determined by deletion analysis. Data indicate that (i) the functional amino terminus of domain III is near amino acid 400; (ii) deletion of various regions in domain II or conversion of cysteines 265 and 268 to serines results in a loss of cytotoxicity which ranged from 10-fold to more than 150-fold, indicating that domain II is essential for full expression of cytotoxicity; (iii) deletion of the amino terminus of domain Ib results in a molecule with somewhat increased cytotoxic activity, indicating that domain Ib is not essential for the cytotoxic effect of TGF alpha-PE40; and (iv) TGF alpha-PE40, produced by denaturing and refolding of insoluble material from inclusion bodies, binds better to EGF receptors and is about 10-fold more cytotoxic to cells bearing EGF receptors than is the secreted form of soluble TGF alpha-PE40.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503515

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

Review 1.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

Review 2.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

Review 3.  Bacterial toxins deliver the goods.

Authors:  A P Pugsley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

4.  Cell-specific toxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6-PE40) on tumor cells.

Authors:  C B Siegall; R P Nordan; D J FitzGerald; I Pastan
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

5.  Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy.

Authors:  Hetal Pandya; Waldemar Debinski
Journal:  BioDrugs       Date:  2012-08-01       Impact factor: 5.807

Review 6.  Antibody-based therapeutics for the treatment of human B cell malignancies.

Authors:  Sivasubramanian Baskar; Natarajan Muthusamy
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

7.  Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression.

Authors:  Christian Bogner; Tobias Dechow; Ingo Ringshausen; Michaela Wagner; Madlen Oelsner; Gloria Lutzny; Thomas Licht; Christian Peschel; Ira Pastan; Robert J Kreitman; Thomas Decker
Journal:  Br J Haematol       Date:  2009-10-11       Impact factor: 6.998

Review 8.  Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

9.  Mapping the minimal contiguous gene segment that encodes functionally active Shiga-like toxin II.

Authors:  L P Perera; J E Samuel; R K Holmes; A D O'Brien
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

10.  Targeted Toxin Gene Therapy Of Breast Cancer Stem Cells Using CXCR1 Promoter And bFGF 5'UTR.

Authors:  Cobra Moradian; Fatemeh Rahbarizadeh
Journal:  Onco Targets Ther       Date:  2019-10-25       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.